Bevacizumab vs ranibizumab—an appraisal of the evidence from CATT and IVAN

Saved in:
Bibliographic Details
Published inEye (London) Vol. 27; no. 3; pp. 289 - 290
Main Authors Ahfat, F G, Zaidi, F H
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.03.2013
Nature Publishing Group
Subjects
631/154/436/108
692/699/67
Angiogenesis Inhibitors - adverse effects
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bevacizumab
editorial
Gastrointestinal Hemorrhage - chemically induced
Humans
Laboratory Medicine
Medicine
Medicine & Public Health
Neoplasms - drug therapy
Ophthalmology
Pharmaceutical Sciences/Technology
Randomized Controlled Trials as Topic
Ranibizumab
Surgery
Surgical Oncology
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity - drug effects
Wet Macular Degeneration - drug therapy
Online AccessGet full text

Cover

More Information
ISSN:0950-222X
1476-5454
DOI:10.1038/eye.2013.1